Pharvaris Reports 92.4% Reduction in Hereditary Angioedema Attacks with Deucrictibant in Long-Term Study
核心洞察
Pharvaris presented long-term clinical data at ACAAI 2025 showing deucrictibant achieved a sustained 92.4% reduction in hereditary angioedema (搜索) attacks over nearly three years.
The company also validated a plasma kinin biomarker assay that may help further characterize bradykinin-mediated angioedema (搜索) and support clinical development.
Pharvaris reported a net loss of €37.14 million for Q3 2025 while advancing toward pivotal Phase 3 trial readouts for RAPIDe-3 in late 2025 and CHAPTER-3 in 2026.
Pharvaris N.V. has reported compelling long-term efficacy data for its investigational hereditary angioedema (搜索) (HAE (搜索)) treatment deucrictibant, demonstrating a sustained 92.4% reduction in HAE attacks over an average of 34 months. The data, presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 conference, represents nearly three years of treatment experience and adds significant clinical validation to the company's lead asset.
Clinical Data Strengthens Development Program
The long-term safety and efficacy results provide crucial evidence supporting deucrictibant's potential as both a prophylactic and on-demand treatment for HAE (搜索). The sustained attack reduction over the extended follow-up period addresses a key clinical need in HAE management, where patients typically experience unpredictable and potentially life-threatening swelling episodes.
Alongside the efficacy data, Pharvaris has validated a plasma kinin biomarker assay that may help further characterize bradykinin-mediated angioedema (搜索). This biomarker development could provide additional clinical insights and support the mechanistic understanding of deucrictibant's therapeutic effects in HAE (搜索) patients.
Pivotal Phase 3 Trials on Horizon
The positive long-term data has enhanced visibility for Pharvaris's upcoming regulatory catalysts. The company expects readouts from two pivotal Phase 3 studies: RAPIDe-3 in late 2025 and CHAPTER-3 in 2026. These trials will evaluate deucrictibant in both prophylactic and on-demand treatment settings, representing critical milestones for the drug's regulatory pathway.
The clinical progress comes as Pharvaris continues to navigate the financial demands of late-stage drug development. The company reported a net loss of €37.14 million for the third quarter of 2025, reflecting ongoing operational expenses and research and development investments.
Market Response and Investment Implications
Following the clinical data presentation, Pharvaris shares experienced significant upward movement, with reports indicating gains of over 11% as investors responded positively to the sustained efficacy results. The Simply Wall St Community has established a fair value estimate of €37.23-€37.45 per share, suggesting unified confidence among analysts despite the company's pre-revenue status.
The clinical validation strengthens Pharvaris's investment narrative centered on deucrictibant's potential to address unmet medical needs in HAE (搜索) treatment. However, the company continues to face elevated financial risks, including ongoing quarterly losses and reliance on equity financing to fund operations through the pivotal trial phases.
HAE Treatment Landscape
Hereditary angioedema (搜索) is a rare genetic disorder characterized by recurrent episodes of swelling that can affect the face, throat, hands, feet, and other body parts. The condition results from deficiencies or dysfunction in C1 esterase inhibitor, leading to increased bradykinin production and vascular permeability. Current treatment options include both prophylactic therapies to prevent attacks and on-demand treatments for acute episodes.
The sustained 92.4% reduction in attack frequency demonstrated by deucrictibant over the long-term follow-up period represents a substantial clinical benefit that could significantly improve quality of life for HAE (搜索) patients. As Pharvaris advances toward its pivotal Phase 3 readouts, the long-term efficacy data provides important evidence supporting the drug's therapeutic potential in this rare disease indication.